Berlin, 13 August 2019. Berlin-based Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a specialist in isotope-related applications in medicine, science and industry, achieved record sales of EUR 89.0 million in the first half of 2019. The sales increased by EUR 8.0 million or 10% when compared to the previous year. Earnings per share rose by 57% to EUR 2.55.

The fastest-growing segment was the Radiopharma segment, mainly driven by continuing strong sales of pharmaceutical radioisotopes to reach a level of EUR 21.7 million, representing an increase of EUR 6.3 million or 41%. The revenue generated by the Isotope Products segment also increased by 5% or EUR 4.2 million to EUR 54.2 million The Radiation Therapy segment, however, recorded a slight drop in sales, achieving EUR 13.2 million, which represents a fall of around 8% year-on-year.

The operating cash flow rose significantly by EUR 9.1 million to EUR 14.2 million. Decisive factors here were the increase of EUR 4.5 million in the result for the period and non-cash effects from depreciation and amortization, which rose by EUR 1.5 million. In total, cash and cash equivalents increased by EUR 2.9 to EUR 57.1 million as at June 30, 2019 as compared with the end of 2018.

For the fiscal year 2019 the management expects sales revenues of around EUR 180 million and earnings of around EUR 4.00 per share. This outlook continues to be based on the assumption that the Euro exchange rate does not exceed USD 1.20.

The complete financial statements can be viewed here:


About Eckert & Ziegler.
Eckert & Ziegler Eckert & Ziegler Strahlen- und Medizintechnik AG with around 800 employees, is one of the world's largest providers of isotope-related components for radiation therapy and nuclear medicine. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the SDAX index of Deutsche Börse.
Contributing to saving lives.

Contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, ,